Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Net Assets
Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has net assets worth CN¥1.46 Billion CNY (≈ $213.78 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.54 Billion ≈ $225.89 Million USD) and total liabilities (CN¥82.76 Million ≈ $12.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Shanghai Yizhong Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.46 Billion |
| % of Total Assets | 94.64% |
| Annual Growth Rate | 32.34% |
| 5-Year Change | 477.0% |
| 10-Year Change | N/A |
| Growth Volatility | 131.8 |
Shanghai Yizhong Pharmaceutical Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Shanghai Yizhong Pharmaceutical Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual net assets of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. For live valuation and market cap data, see market value of Shanghai Yizhong Pharmaceutical Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.41 Billion ≈ $205.60 Million |
-4.08% |
| 2023-12-31 | CN¥1.46 Billion ≈ $214.35 Million |
+11.04% |
| 2022-12-31 | CN¥1.32 Billion ≈ $193.04 Million |
+12.22% |
| 2021-12-31 | CN¥1.18 Billion ≈ $172.02 Million |
+382.76% |
| 2020-12-31 | CN¥243.51 Million ≈ $35.63 Million |
-8.23% |
| 2019-12-31 | CN¥265.35 Million ≈ $38.83 Million |
+25.06% |
| 2018-12-31 | CN¥212.18 Million ≈ $31.05 Million |
+7.40% |
| 2017-12-31 | CN¥197.57 Million ≈ $28.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Yizhong Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19127598443.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥164.01 Million | 11.67% |
| Common Stock | CN¥206.59 Million | 14.70% |
| Other Comprehensive Income | CN¥57.38 Million | 4.08% |
| Other Components | CN¥977.04 Million | 69.54% |
| Total Equity | CN¥1.41 Billion | 100.00% |
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jefferson Capital, Inc. Common Stock
NASDAQ:JCAP
|
$1.18 Billion |
|
T1 Energy Inc.
NYSE:TE
|
$1.18 Billion |
|
Harbin Electric Coporation Jiamusi Electric Machine Co Ltd
SHE:000922
|
$1.18 Billion |
|
Beijing Shunxin Agriculture Co Ltd
SHE:000860
|
$1.18 Billion |
|
Beijing Cuiwei Tower Co Ltd
SHG:603123
|
$1.18 Billion |
|
Shandong Denghai Seeds Co Ltd
SHE:002041
|
$1.18 Billion |
|
Suburban Propane Partners LP
NYSE:SPH
|
$1.18 Billion |
|
United States Steel Corp
BA:X
|
$1.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Yizhong Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,464,836,602 to 1,405,020,800, a change of -59,815,802 (-4.1%).
- Net income of 6,975,284 contributed positively to equity growth.
- Dividend payments of 49,794,721 reduced retained earnings.
- Share repurchases of 37,240,964 reduced equity.
- Other comprehensive income increased equity by 1,503,782.
- Other factors increased equity by 18,740,817.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥6.98 Million | +0.5% |
| Dividends Paid | CN¥49.79 Million | -3.54% |
| Share Repurchases | CN¥37.24 Million | -2.65% |
| Other Comprehensive Income | CN¥1.50 Million | +0.11% |
| Other Changes | CN¥18.74 Million | +1.33% |
| Total Change | CN¥- | -4.08% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Yizhong Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.78x to 6.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.97 | CN¥38.93 | x |
| 2018-12-31 | CN¥2.03 | CN¥38.93 | x |
| 2019-12-31 | CN¥1.68 | CN¥38.93 | x |
| 2020-12-31 | CN¥3.06 | CN¥38.93 | x |
| 2021-12-31 | CN¥7.43 | CN¥38.93 | x |
| 2022-12-31 | CN¥8.33 | CN¥38.93 | x |
| 2023-12-31 | CN¥7.12 | CN¥38.93 | x |
| 2024-12-31 | CN¥6.04 | CN¥38.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Yizhong Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.02%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.03x
- Recent ROE (0.50%) is above the historical average (-14.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -5.09% | 0.00% | 0.00x | 1.08x | CN¥-29.82 Million |
| 2018 | -5.93% | 0.00% | 0.00x | 1.08x | CN¥-33.81 Million |
| 2019 | -118.79% | 0.00% | 0.00x | 1.05x | CN¥-341.76 Million |
| 2020 | -8.97% | 0.00% | 0.00x | 1.06x | CN¥-46.20 Million |
| 2021 | -0.34% | -98.03% | 0.00x | 1.02x | CN¥-121.55 Million |
| 2022 | 10.83% | 60.54% | 0.17x | 1.03x | CN¥10.94 Million |
| 2023 | 11.03% | 44.84% | 0.23x | 1.07x | CN¥15.07 Million |
| 2024 | 0.50% | 4.02% | 0.12x | 1.03x | CN¥-133.53 Million |
Industry Comparison
This section compares Shanghai Yizhong Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,133,881,544
- Average return on equity (ROE) among peers: 2.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Yizhong Pharmaceutical Co Ltd (688091) | CN¥1.46 Billion | -5.09% | 0.06x | $1.18 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $868.76 Million | 4.89% | 3.05x | $639.13 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $775.01 Million | 2.45% | 0.87x | $378.07 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $5.07 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $662.32 Million | 12.10% | 0.68x | $2.59 Billion |
| Wedge Industrial Co Ltd (000534) | $692.08 Million | 2.78% | 1.05x | $1.97 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $13.23 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.49 Billion | 5.19% | 0.85x | $1.11 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $302.41 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.75 Billion | 0.46% | 2.42x | $956.43 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.16 Billion |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more